SEATTLE, May 11, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced its support of the 19th Annual National Women’s Health Week lead by the U.S. Department of Health and Human Services’ (HHS) Office on Women’s Health. The annual observance kicks off on Mother’s Day, May 13th and is celebrated through May 19th, 2018. The week serves as a reminder for women to make their health a priority and build positive health habits for life.
“As a leading clinical-stage company developing treatment options for breast cancer, we also encourage women to make their health a priority. Managing cardiovascular risks and preventing cancers with screening tests, like the cervical Pap smear and the breast mammogram, are important steps for a long and healthy life,” said Janet R Rea, MSPH, RAC, SVP of Regulatory, Quality and Clinical Affairs for Atossa. “Early testing for both cardiovascular and pre-cancerous conditions that can lead to a variety of cancers is immensely valuable to women and their loved ones.”
For more information regarding the Women’s Health Week, including information for local services, please see https://www.womenshealth.gov/nwhw/about.
About Atossa Genetics
Atossa Genetics Inc. is a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions. For more information, please visit www.atossagenetics.com.
Forward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with any variation between preliminary and final clinical results, actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa including those needed to commence studies, lower than anticipated rate of patient enrollment, estimated market size of drugs under development, the safety and efficacy of Atossa's products and services, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others with respect to fulvestrant, such as patent rights, potential market sizes for Atossa’s drugs under development and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.
Atossa Genetics Company Contact:
Atossa Genetics Inc.
CFO and General Counsel
Office: 866 893-4927
Investor Relations Contact:
377 Oak Street
Garden City, NY 11530
Office: 516 222-2560
Source: Atossa Genetics Inc.